PCM
ARIA

Prelude Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Prelude Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,600
Closed -$36K – 2339
2014
Q3 		$36K Buy
6,600
+800
+14% +$4.67K 0.01% 1535
2014
Q2 		$37K Sell
5,800
-1,700
-23% -$11.7K ﹤0.01% 1551
2014
Q1 		$60K Buy
7,500
+6,500
+650% +$50.6K 0.01% 1233
2013
Q4 		$7K Sell
1,000
-1,000
-50% -$5.4K ﹤0.01% 1539
2013
Q3 		$37K Buy
+2,000
New +$38.8K 0.01% 1004

Other funds holding ARIA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Prelude Capital Management's ARIA Position: Q3 2016 in Review

Prelude Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2016, closing a stake of 8,600 shares — an estimated $64K sold.

Prelude Capital Management first reported a position in ARIA in Q2 2013 and held it in 10 quarters. The position peaked at $506K in Q2 2013. 202 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

  • Prelude Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Prelude Capital Management sold 8,600 Ariad Pharmaceuticals Inc shares in Q3 2016, an estimated $64K.
  • Prelude Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
  • Prelude Capital Management's Ariad Pharmaceuticals Inc position peaked at $506K in Q2 2013.
  • 202 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on Prelude Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.